In the first line setting, the HR was 0.34 (95% CI, 0.16–0.72) with a p value of 0.054, a trend for benefit of borderline significance.
← all excerpts
Long-Term Results with Everolimus in Advanced Hormone Receptor Positive Breast Cancer in a Multicenter National Real-World Observational Study.
1
—
—